Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.

Biotechnology

Allena Pharmaceuticals

Louis Brenner

Laurie Berggren

Richard Katz

Geoffrey Swire

Alicja Januszewicz

Stephen Yu

David J. Clark

Hugh Wight

The board of directors at Allena Pharmaceuticals has a history of experience with companies such as Versantis AG and Chiasma. They have also been educated in fields such as finance and business. This provides them with the knowledge and experience needed to make decisions that will benefit the company.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Allena Pharmaceuticals

Leadership Team

CEO and Executive Team